Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Basic research

Preclinical model of prostate cancer bone metastasis

Nature Reviews Urology volume 11, page 244 (2014)Cite this article

Subjects

An orthotopic xenograft model of castration-resistant prostate cancer bone metastasis has been created using tibial injection of luciferase-expressing prostate cancer cells. Imaging enabled quantitation of tumour volume and calculation of an apparent diffusion coefficient (ADC). Tumour luminescence was significantly reduced, and ADC was significantly increased, after treatment with cabozantinib, demonstrating a therapeutic response.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Graham, T. J. et al. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J. Natl Cancer Inst. 10.1093/jnci/dju033

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Preclinical model of prostate cancer bone metastasis. Nat Rev Urol 11, 244 (2014). https://doi.org/10.1038/nrurol.2014.81

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2014.81

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing